Cardiovascular disease remains the leading cause of death globally, with most interventions targeting LDL cholesterol while triglyceride-rich lipoproteins receive less attention. This clinical trial demonstrates that directly targeting these alternative lipid pathways can meaningfully reduce coronary plaque burden, potentially opening new therapeutic avenues for millions with elevated triglycerides.
The ESSENCE-TIMI 73b imaging substudy tracked 468 adults with moderate hypertriglyceridemia using coronary computed tomography angiography over 12 months. Participants receiving olezarsen, an antisense oligonucleotide targeting apolipoprotein C-III, experienced dramatic reductions in triglycerides (64%) and remnant cholesterol (72%) while maintaining stable LDL cholesterol levels. Most significantly, non-calcified plaque volume decreased substantially compared to placebo controls, representing direct evidence of coronary atherosclerosis regression.
This finding challenges the conventional wisdom that LDL cholesterol reduction represents the primary pathway for plaque modification. The magnitude of plaque reduction achieved through triglyceride-focused intervention suggests that remnant lipoproteins play a more significant role in atherosclerosis progression than previously recognized. For the estimated 25% of adults with elevated triglycerides, this represents a paradigm shift toward personalized lipid management based on individual lipoprotein profiles rather than one-size-fits-all LDL targets.
However, the 12-month timeframe limits understanding of long-term cardiovascular outcomes. While plaque volume reduction typically correlates with reduced heart attack risk, definitive cardiovascular endpoint trials remain necessary. Additionally, the antisense oligonucleotide approach requires injection therapy, potentially limiting widespread adoption compared to oral medications.